Henderson Amy, Korner-Bitensky Nicol, Levin Mindy
Department of Neurology and Neurosurgery, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Top Stroke Rehabil. 2007 Mar-Apr;14(2):52-61. doi: 10.1310/tsr1402-52.
It is estimated that 50% to 75% of individuals who experience a stroke have persistent impairment of the affected upper limb (UL). There is a need to identify the best training strategies for retraining motor function of the UL. One intervention showing promise is virtual reality (VR), using either immersive or nonimmersive technology. Before recommending VR for use in clinical practice, it is important to understand the evidence regarding its effectiveness.
Two questions about the effectiveness of VR for UL rehabilitation in stroke were posed: (1) Is the use of immersive VR more effective than conventional therapy or no therapy in the rehabilitation of the UL in patients with hemiplegia? (2) Is the use of nonimmersive VR more effective than conventional therapy or no therapy in the rehabilitation of the UL in patients with hemiplegia?
There is level 1b evidence suggesting an advantage to training in immersive VR environments versus no therapy in UL rehabilitation, and level 5 evidence for training in immersive VR versus conventional therapy. There is level 4 evidence showing conflicting results for training in nonimmersive VR versus no therapy, and level 2b evidence for training in nonimmersive VR versus conventional therapy.
The current evidence on the effectiveness of using VR in the rehabilitation of the UL in patients with stroke is limited but sufficiently encouraging to justify additional clinical trials in this population.
据估计,经历过中风的个体中有50%至75%的人受影响的上肢存在持续性损伤。需要确定用于重新训练上肢运动功能的最佳训练策略。一种显示出前景的干预措施是虚拟现实(VR),可使用沉浸式或非沉浸式技术。在推荐将VR用于临床实践之前,了解其有效性的证据很重要。
提出了两个关于VR对中风患者上肢康复有效性的问题:(1)在偏瘫患者的上肢康复中,使用沉浸式VR是否比传统疗法或不治疗更有效?(2)在偏瘫患者的上肢康复中,使用非沉浸式VR是否比传统疗法或不治疗更有效?
有1b级证据表明,在沉浸式VR环境中训练相对于不治疗在上肢康复方面具有优势,而在沉浸式VR训练与传统疗法对比方面有5级证据。有4级证据表明非沉浸式VR训练与不治疗的结果相互矛盾,在非沉浸式VR训练与传统疗法对比方面有2b级证据。
目前关于VR用于中风患者上肢康复有效性的证据有限,但足以令人鼓舞,有理由在该人群中开展更多临床试验。